Synthetic polymer-drug conjugates for human therapy

Handbook of Materials for Nanomedicine

Volumn , Issue , 2010, Pages 5-79

  Ulbrich, Karel ^a   Subr, Vladimir ^a  

^a INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84871192683     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4032/9789814267588     Document Type: Chapter

References (273)

1. A. A. Adjei, and J. K. Buolamwini, Novel Anticancer Agents. Strategies for Discovery and Clinical Testing, Elsevier, Academic Press, Amsterdam (2006).
2. L. Andersson, J. Davies, R. Duncan, P. Ferruti, J. Ford, S. Kneller, R. Mendichi, G. Pasut, O. Schiavon, C. Summerford, A. Tirk, F. M. Veronese, V. Vincenzi and G. F. Wu, Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyldoxorubicin pendant side chains: Synthesis and evaluation as anticancer conjugates, Biomacromolecules, 6, 914-926 (2005).
3. M. Aoshima, S. Tsukagoshi, Y. Sakurai, J. I. Ohishi, T. Ishida and H. Kobayashi, N4-Behenoyl-1-β-D-arabinofuranosylcytosine as a potential new antitumor agent, Cancer Res., 37, 2481-2486 (1977).
4. F. Aulenta, W. Hayes and S. Rannard, Dendrimers: a new class of nanoscopic containers and delivery devices, Eur. Polym. J., 39, 1741-1771 (2003).
5. K. D. Bagshawe, Antibody-directed enzyme prodrug therapy (ADEPT) for cancer, Expert Rev. Anticancer Ther., 6, 1421-1431 (2006).
6. K. D. Bagshawe, S. K. Sharma and R. H. J. Begent, Antibodydirected enzyme prodrug therapy (ADEPT) for cancer, Expert Opin. Biol. Ther., 4, 1777-1789 (2004).
7. P. Bailon, A. Palleroni, C. A. Schaffer, C. L. Spence, W. J. Fung, J. E. Porter, G. K. Ehrlich, W. Pan, Z. X. Xu, M. W. Modi, A. Farid andW. Berthold, Rational design of a potent, long-lasting formof interferon: A 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C, Bioconjugate Chem., 12, 195-202 (2004).
8. D. Bayley, M. R. Sancho, J. Brown, L. Brookman, K. Petrák, P. Goddard and A. Steward, Soluble polymeric carriers for drug delivery. 6. Preparation and biodistribution of N5-hydroxyethyl-L-glutamine-co-L-glutamic acid copolymers in rats, J. Bioact. Compat. Polym., 8, 51-68 (1993).
9. M. Berna, D. Dalzoppo, G. Pasut, M. Manunta, L. Izzo, A. T. Jones, R. Duncan and F. M. Veronese, Novel monodisperse PEG-dendrons as newtools for targeted drug delivery: Synthesis, characterization and cellular uptake, Biomacromolecules, 7, 146-153 (2006).
10. D. Bissett, J. Cassidy, J. S. de Bono, F. Muirhead, M. Main, L. Robson, D. Fraier, M. L. Magne, C. Pellizzoni, M. G. Porro, R. Spinelli, W. Speed and C. Twelves, Phase I and pharmacokinetic (PK) study ofMAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT), Br. J. Cancer, 91, 50-55 (2004).
11. L. Blau, R. F. Menegon and M. C. Chung, Prodrug activation by enzyme, a promising strategy for chemotherapy, Quim. Nova, 29, 1307-1317 (2006).
12. C. Braud, C. Bunel and M. Vert, (1985). Poly(β-malic acid) - a new polymeric drug-carrier - evidence for degradation in vitro, Polym. Bull., 13, 293-299 (2006).
13. R. Bukowski, M. S. Ernstoff, M. E. Gore, J. J. Nemunaitis, R. Amato, S. K. Gupta and C. L. Tendler, Pegylated interferon α2b treatment for patients with solid tumors: A phase I/II study, J. Clin. Oncol., 20, 3841-3849 (2002).
14. H. Bundgaard, The double prodrug concept and its applications, Adv. Drug Delivery Rev., 3, 39-65 (1989).
15. G. Caldwell and E. W. Neuse, Synthesis of water-soluble polyamidoamines for biomedical applications. 1. Carboxylfunctionalized polymers as potential-drug carriers, South Afr. J. Chem. -Suid-Afr. Tydskr. Chem., 45, 93-102 (1992).
16. G. Caldwell, E. W. Neuse and A. Stephanou, Synthesis of watersoluble polyamidoamines for biomedical applications. II. Polymers possessing intrachain-type secondary amino groups suitable for side-chain attachment, J. Appl. Polym. Sci., 50, 393-401 (1993).
17. A. P. Chapman, PEGylated antibodies and antibody fragments for improved therapy: A review, Adv. Drug Delivery Rev., 54, 531-545 (2002).
18. A. P. Chapman, P. Antoniw, M. Spitali, S. West, S. Stephens and D. J. King, Therapeutic antibody fragments with prolonged in vivo half-lives, Nat. Biotechnol., 17, 780-783 (1999).
19. J. Činátl, O. Štěrba, E. Paluska, V. Polednová and J. Kopecěk, New types of synthetic infusion solutions. The effect of Duxon on the cell prolifereation in vitro (in Czech), Česk. Farm., 29, 134-138 (1980).
20. Y. H. Choe, C. D. Conover, D. C. Wu, M. Royzen, Y. Gervacio, V. Borowski, M. Mehlig and R. B. Greenwald, Anticancer drug delivery systems: Multi-loaded N-4-acyl poly(ethylene glycol) prodrugs of ara-C. II. Efficacy in ascites and solid tumors, J. Control. Release, 79, 55-70 (2002).
21. Y. H. Choe, C. D. Conover, D. C. Wu, M. Royzen and R. B. Greenwald, Anticancer drug delivery systems: N-4-acyl poly(ethyleneglycol) prodrugs of ara-C I. Efficacy in solid tumors, J. Control. Release, 79, 41-53 (2002).
22. Y. H. Choe, R. B. Greenwald, C. D. Conover, H. Zhao, C. B. Longley, S. Y. Guan, Q. X. Zhao and J. Xia, PEG prodrugs of 6-mercaptopurine for parenteral administration using benzyl elimination of thiols, Oncol. Res., 14, 455-468 (2004).
23. W. M. Choi, P. Kopečková, T. Minko and J. Kopeček, Synthesis of HPMA copolymer containing adriamycin bound via an acid-labile spacer and its activity toward human ovarian carcinoma cells, J. Bioact. Compat. Polym., 14, 447-456 (1999).
24. P. Chytil, T. Etrych, Koňák, Č, M. Šírová, T. Mrkvan, J. Boucěk, B. Říhová and K. Ulbrich, New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting, J. Control. Release, 127, 121-130 (2008).
25. V. Chytrý and K. Ulbrich, Conjugate of doxorubicin with thermosensitive polymer drug carrier, J. Bioactive Compat. Polym., 16, 427-439 (2001).
26. V. Chytrý, A. Vrána and J. Kopeček, Synthesis and activity of a polymer which contains insulin covalently bound on a copolymer of N-(2-hydroxypropyl)methacrylamide and Nmethacryloyl-diglycyl-p-nitrophenyl ester, Makromol. Chem., 179, 329-336 (1978).
27. C. D. Conover, R. B. Greenwald, A. Pendri and K. L. Shum, Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs, Anti-Cancer Drug Design, 14, 499-506 (1999).
28. V. Cuchelkar, P. Kopečková and J. Kopeček, Synthesis and biological evaluation of disulfide-linked HPMA copolymermesochlorin e6 conjugates, Macromol. Biosci., 8, 375-383 (2008).
29. A. S. De Groot and D.W. Scott, Immunogenicity of protein therapeutics, Trends in Immunology, 28, 482-490 (2007).
30. A. DeMarre, H. Soyez, E. Schacht, M. A. Shoaibi, L. W. Seymour and B. Říhová, Synthesis and evaluation of macromolecular prodrugs of mitomycin-C, J. Control. Release, 36, 87-97 (1995).
31. A. J. Domb, Polysaccharides as carriers of bioactive agents for medical applications, in Natural-Based Polymers for Biomedical Applications, Ed., R. L. Reis, Woodhead Publishing Ltd., Cambridge, (2008).
32. R. Duncan, The dawning era of polymer therapeutics, Nat. Rev. Drug Discov., 2, 347-360 (2003).
33. R. Duncan, N-(2-Hydroxypropyl)methacrylamide copolymer conjugates, in Drugs and the Pharmaceutiutical Sciences, Ed., J. Swarbrick, Taylor & Francis, Boca Raton, pp. 1-92 (2005).
34. R. Duncan, Polymer conjugates as anticancer nanomedicines, Nat. Rev. Cancer, 6, 688-701 (2006)
35. R. Duncan, Designing polymer conjugates as lysosomotropic nanomedicines, Biochem. Soc. Trans., 35, 56-60 (2007).
36. R. Duncan, H. C. Cable, J. B. Lloyd, P. Rejmanová and J. Kopeček, Degradation of side-chains of N-(2-hydroxypropyl) methacrylamide copolymers by lysosomal thiol-proteinases, Biosci. Rep., 2, 1041-1046 (1982).
37. R. Duncan, H. C. Cable, J. B. Lloyd, P. Rejmanová and J. Kopeček, Polymers containing enzymatically degradable bonds. 7. Design of oligopeptide side-chains in N-(2-hydroxypropyl)methacrylamide copolymers to promote efficient degradation by lysosomal enzymes, Makromol. Chem., 184, 1997-2008 (1983).
38. R. Duncan, H. C. Cable, J. Strohalm and J. Kopeček, Pinocytic capture and exocytosis of rat immunoglobulin IgG-N-(2-hydroxypropyl)methacrylamide copolymer conjugates by rat visceral yolk sacs cultured in vitro, Biosci. Rep., 6, 869-877 (1986).
39. R. Duncan, S. Gac-Breton, R. Keane, R. Musila, Y. N. Sat, R. Satchi and F. Searle, Polymer-drug conjugates, PDEPT and PELT: Basic principles for design and transfer from the laboratory to clinic, J. Control. Release, 74, 135-146 (2001).
40. R. Duncan, I. C. Hume, P. Kopečková, K. Ulbrich, J. Strohalm and J. Kopeček, Anticancer agents coupled to N-(2-hydroxypropyl) methacrylamide copolymers. 3. Evaluation of adriamycin conjugates against mouse leukaemia L1210 in vivo, J. Control. Release, 10, 51-63 (1989).
41. R. Duncan, I. C. Hume, H. J. Yardley, P. A. Flanagan, K. Ulbrich, V. Šubr and J. Strohalm, Macromolecular prodrugs for use in targeted cancer-chemotherapy-Melphalan covalently coupled to N-(2-hydroxypropyl)methacrylamide copolymers, J. Control. Release, 16, 121-136 (1991).
42. R. Duncan and J. Kopeček, Soluble synthetic polymers as potential drug carriers, Adv. Polym. Sci., 57, 51-101 (1984).
43. R. Duncan, J. Kopeček, P. Rejmanová and J. B. Lloyd, Targeting of N-(2-hydroxypropyl)methacrylamide copolymers to liver by incorporation of galactose residues, Biochim. Biophys. Acta, 755, 518-521 (1983).
44. R. Duncan, P. Kopečková-Rejmanová, J. Strohalm, I. C. Hume, H. C. Cable, J. Pohl, J. B. Lloyd and J. Kopeček, Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 1. Evaluation of daunomycin and puromycin conjugates in vitro, Br. J. Cancer, 55, 165-174 (1987).
45. R. Duncan, P. Kopečková-Rejmanová, J. Strohalm, I. C. Hume, J. B. Lloyd and J. Kopeček, Anticancer agents coupled N-(2-hydroxypropyl)methacrylamide copolymers. 2. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia, Br. J. Cancer, 57, 147-156 (1988).
46. R. Duncan, P. Rejmanová, J. Kopeček and J. B. Lloyd, Pinocytic uptake and intracellular degradation of N-(2-hydroxypropyl) methacrylamide copolymers. A potential drug delivery system, Biochim. Biophys. Acta, 678, 143-150 (1981).
47. R. Duncan, H. Ringsdorf and R. Satchi-Fainaro, Polymer therapeutics: Polymers as drugs, drug and protein conjugates and gene delivery systems: Past, present and future opportunities, in Advances in Polymer Science, Polymer Therapeutics I, Eds. R. Satchi-Fainaro and R. Duncan, Berlin/Heidelberg, 1-8 (2006).
48. R. Duncan, L. W. Seymour, K. B. O'Hare, P. A. Flanagan, S. R. Wedge, I. C. Hume, K. Ulbrich, J. Strohalm, V. Šubr, F. Spreafico, M. Grandi, M. Ripamonti, M. Farao and A. Suarato, Preclinical evaluation of polymer-bound doxorubicin, J. Control. Release, 19, 331-346 (1992).
49. R. Duncan, L. W. Seymour, L. Scarlett, J. B. Lloyd, P. Rejmanová and J. Kopeček, Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats, Biochim. Biophys. Acta, 880, 62-71 (1986).
50. M. Dvoák, P. Kopečková and J. Kopeček, High-molecular weight HPMA copolymer-adriamycin conjugates, J. Control. Release, 60, 321-332 (1999).
51. T. Etrych, P. Chytil, M. Jelínková, B. Říhová and K. Ulbrich, Synthesis of HPMA copolymers containing doxorubicin bound via a hydrazone linkage. Effect of spacer on drug release and in vitro cytotoxicity, Macromol. Biosci., 2, 43-52 (2002).
52. T. Etrych, P. Chytil, P. Mrkvan, M. Šírová, B. Říhová and K. Ulbrich, Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting, J. Control. Release, 132, 284-192 (2008).
53. T. Etrych, P. Chytil, K. Ulbrich, T. Mrkvan and B. Říhová, Grafted macromolecular conjugates of doxorubicin with anticancer activity and method of their preparation, PV 2006-592; WO 2008/034391, CZ 298945 (B6): Czech Republic (2008).
54. T. Etrych, T. Mrkvan, B. Říhová and K. Ulbrich, Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy, J. Control. Release, 122, 31-38 (2007).
55. T. A. Fadl, T. Hasegawa, A. F. Youssef, H. H. Farag, F. A. Omar and T. Kawaguchi, Synthesis and investigation of N-4-substituted cytarabine derivatives as prodrugs, Pharmazie, 50, 382-387 (1995).
56. P. Ferruti, M. A. Marchisio and R. Duncan, Poly(amido-amine)s: Biomedical applications, Macromol. Rapid Commun., 23, 332-355 (2002).
57. P. Ferruti, E. Ranucci, F. Trotta, E. Gianasi, E. G. Evagorou, M. Wasil, G. Wilson and R. Duncan, Synthesis, characterisation and antitumour activity of platinum (II) complexes of novel functionalised poly(amidoamine)s, Macromol. Chem. Phys., 200, 1644-1654 (1999).
58. D. R. Ferry, L. W. Seymour, D. Anderson, S. Hesslewood, P. Julyan, C. Boivin, R. Poyner, P. Guest, J. Doran and D. J. Kerr, Phase I trial or liver targeted HPMA copolymer of doxorubicin PK2, pharmacokinetics, spect imaging of I123-PK2 and activity in hepatoma, Br. J. Cancer, 80, 21 (1999).
59. P. A. Flanagan, P. Kopečková, J. Kopeček and R. Duncan, Evaluation of protein-N-(2-hydroxypropyl)methacrylamide copolymer conjugates as targetable drug carriers. 1. Binding, pinocytic uptake and intracellular distribution of transferrin and anti-transferrin receptor antibody conjugates, Biochim. Biophys. Acta, 993, 83-91 (1989).
60. P. Fournie, D. Domurado, P. Guerin, C. Braud, M. Vert and R. Pontikis, In vivo fate of repeat-unit-radiolabeled poly(β-malic acid), A potential-drug carrier, J. Bioactive Compat. Polym., 7, 113-129 (1992).
61. D. Fraier, V. Cenacchi and E. Frigerio, Determination of a new polymer-bound paclitaxel derivative (PNU 166945), free paclitaxel and 7-epipaclitaxel in dog plasma and urine by reversed-phase high-performance liquid chromatography with UV detection, J. Chromatogr. A, 797, 295-303 (1998).
62. D. Gaal and F. Hudecz, Low toxicity and high antitumour activity of daunomycin by conjugation to an immunopotential amphoteric branched polypeptide, Eur. J. Cancer, 34, 155-161 (1998).
63. S. Q. Gao, Y. Sun, P. Kopečková, C. M. Peterson and J. Kopeček, Pharmacokinetic modeling of absorption behavior of 9-aminocamptothecin (9-AC) released fromcolon-specific HPMA Copolymer-9-AC conjugate in rats, Pharm. Res., 25, 218-226 (2008).
64. E. Gianasi, R. G. Buckley, J. Latigo, M. Wasil and R. Duncan, HPMA copolymers platinates containing dicarboxylato ligands. Preparation, characterisation and in vitro and in vivo evaluation, J. Drug Target., 10, 549-556 (2002).
65. A. Godwin, M. Hartenstein, A.H. E. Muller and S. Brocchini, Narrow molecular weight distribution precursors for polymer-drug conjugates, Angew. Chem. Int. Edit., 40, 594-597 (2001).
66. M. L. Graham, Pegaspargase: A review of clinical studies, Adv. Drug Delivery Rev., 55, 1293-1302 (2003).
67. F. Greco, M. J. Vicent, S. Gee, A. T. Jones, J. Gee, R. I. Nicholson and R. Duncan, Investigating themechanismof enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells, J. Control. Release, 117, 28-39 (2007).
68. M. J. Greco, J. E. Kemnitzer, J. D. Fox, J. K. Choe, J. Kohn, D. J. Riley and G. J. Poiani, Polymer of proline analogue with sustained antifibrotic activity in lung fibrosis, Am. J. Respir. Crit. Care Med., 155, 1391-1397 (1997).
69. R. B. Greenwald, PEG drugs: an overview, J. Control. Release, 74, 159-171 (2001).
70. R. B. Greenwald, Y. H. Choe, J. McGuire and C. D. Conover, Effective drug delivery by PEGylated drug conjugates, Adv. Drug Delivery Rev., 55, 217-250 (2003).
71. R. B. Greenwald, A. Pendri and D. Bolikal, Highly water-soluble taxol derivatives: 7-polyethylene glycol carbamates and carbonates, J. Org. Chem., 60, 331-336 (1995).
72. R. B. Greenwald, A. Pendri, A. Martinez, C. Gilbert and P. Bradley, PEG thiazolidine-2-thione, a novel reagent for facile protein modification: Conjugation of bovine hemoglobin, Bioconjugate Chem., 7, 638-641 (1996).
73. R. Haag and F. Kratz, Polymer therapeutics: Concepts and applications, Angew. Chem. Int. Edit., 45, 1198-1215 (2006).
74. T. Hirano, T. Todoroki, R. Morita, S. Kato, Y. Ito, K. H. Kim, P. G. Shukla, F. Veronese, H. Maeda and S. Ohashi, Antiinflammatory effect of the conjugate of superoxide dismutase with the copolymer of divinyl ether andmaleic anhydride against rat re-expansion pulmonary edema, J. Control. Release, 48, 131-139 (1997).
75. K. Hoste, K. De Winne and E. Schacht, Polymeric prodrugs, Int. J. Pharm., 277, 119-131 (2004).
76. K. Hoste, E. Schacht and B. Říhová, Synthesis and biological evaluation of PEG-substituted macromolecular prodrugs of mitomycin C, J. Bioactive Compat. Polym., 17, 123-138 (2002).
77. M. Hrubý, T. Etrych, J. Kučka, M. Forsterová and K. Ulbrich, Hydroxybisphosphonate-containing polymeric drug-delivery systems designed for targeting into bone tissue, J. Appl. Polym. Sci., 101, 3192-3201 (2006).
78. M. Hrubý, J. Kučka, O. Lebeda, H. Macková, M. Babič, M. Koňák, Studenovský, A. Sikora, J. Kozempel and K. Ulbrich, New bioerodable thermoresponsive polymers for possible radiotherapeutic applications, J. Control. Release, 119, 25-33 (2007).
79. S. Hwang, N. Tamilarasu, K. Kibler, H. Cao, A. Ali, Y. H. Ping, K. T. Jeang and T. M. Rana, Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication, J. Biol. Chem., 278, 39092-39103 (2003).
80. R. J. Ignoffo, Novel oral fluoropyrimidines in the treatment of metastatic colorectal cancer, Am. J. Health-Syst. Pharm., 56, 2417-2428 (1999).
81. M. Jelínková, J. Strohalm, T. Etrych, K. Ulbrich and B. Říhová, Starlike versus classic macromolecular prodrugs: two different antibody-targeted HPMA copolymers of doxorubicin studied in vitro and in vivo as potential anticancer drugs, Pharm. Res., 20, 1558-1564 (2003).
82. M. Jelínková, J. Strohalm, D. Plocová, V. Šubr, M. Št'astný, K. Ulbrich and Říhová, B, Targeting of human and mouse T-lymphocytes by monoclonal antibody HPMA copolymer doxorubicin conjugates directed against different T-cell surface antigens, J. Control. Release, 52, 253-270 (1998).
83. P. J. Julyan, L.W. Seymour, D. R. Ferry, S. Daryani, C.M. Boivin, J. Doran, M. David, D. Anderson, C. Christodoulou, A. M. Young, S. Hesslewood and D. J. Kerr, Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine, J. Control. Release, 57, 281-290 (1999).
84. A. Kakinoki, Y. Kaneo, Y. Ikeda, T. Tanaka and K. Fujita, Synthesis of poly(vinyl alcohol)-doxorubicin conjugates containing cis-aconityl acid-cleavable bond and its isomer dependent doxorubicin release, Biol. Pharm. Bull., 31, 103-110 (2008).
85. H. Kamada, Tsutsumi, Y. Sato-Kamada, K. Yamamoto, Y. Yoshioka, Y. Okamoto, T. Nakagawa, S. Nagata and T. Mayumi, Synthesis of a poly(vinylpyrrolidone-co-dimethyl maleic anhydride) co-polymer and its application for renal drug targeting, Nat. Biotechnol., 21, 399-404 (2003).
86. H. Kamada, Y. Tsutsumi, Y. Yoshioka, Y. Yamamoto, H. Kodaira, S. Tsunoda, T. Okamoto, T. Mukai, H. Shibata, S. Nakagawa and T. Mayumi, Design of a pH-sensitive polymeric carrier for drug release and its application in cancer therapy, Clin. Cancer Res., 10, 2545-2550 (2004).
87. Y. Kaneda, Y. Tsutsumi, Y. Yoshioka, H. Kamada, Y. Yamamoto, H. Kodaira, S. Tsunoda, T. Okamoto, Y. Mukai, H. Shibata, S. Nakagawa and T. Mayumi, The use of PVP as a polymeric carrier to improve the plasma half-life of drugs, Biomaterials, 25, 3259-3266 (2004).
88. Y. Kaneda, Y. Yamamoto, H. Kamada, S. Tsunoda, Y. Tsutsumi, T. Hirano and T. Mayumi, Antitumor activity of tumor necrosis factor α conjugated with divinyl ether and maleic anhydride copolymer on solid tumors in mice, Cancer Res., 58, 290-295 (1998).
89. Y. Kasuya, Z. R. Lu, P. Kopečková and J. Kopeček, Improved synthesis and evaluation of 17-substituted aminoalkylgeldanamycin derivatives applicable to drug delivery systems, Bioorg. Med. Chem. Lett., 11, 2089-2091 (2001).
90. Y. Kasuya, Z. R. Lu, P. Kopečková, S. E. Tabibi and J. Kopeček, Influence of the structure of drug moieties on the in vitro efficacy of HPMA copolymer-geldanamycin derivative conjugates, Pharm. Res., 19, 115-123 (2002).
91. T. Kawaguchi, H. Asakawa, Y. Tashiro, K. Juni and T. Sueishi, Stability, specific binding-activity and plasma-concentration in mice of an oligodeoxynucleotide modified at 5'-terminal with poly(ethylene glycol), Biol. Pharm. Bull., 18, 474-476 (1995).
92. L. Kelland, Discontinued drugs in 2005: oncology drugs, Expert Opin. Investig. Drugs, 15, 1309-1318 (2006).
93. J. Khandare and T. Minko, Polymer-drug conjugates: Progress in polymeric prodrugs, Prog. Polym. Sci., 31, 359-397 (2006).
94. O. Kinstler, G. Molineux, M. Treuheit, D. Ladd and C. Gegg, Mono-N-terminal poly(ethylene glycol)-protein conjugates, Adv. Drug Delivery Rev., 54, 477-485 (2002).
95. L. L. Komane, E. H. Mukaya, E. W. Neuse and van C. E. J. Rensburg, Macromolecular antiproliferative agents featuring dicarboxylato-chelated platinum, J. Inorg. Organomet. Polym. Mater., 18, 111-123 (2008).
96. J. Kopeček and H. Bažilová, Poly[N-(2-hydroxypropyl)methacrylamide]. I. Radical polymerization and copolymerization, Eur. Polym. J., 9, 7-14 (1973).
97. J. Kopeček, I. Cífková, P. Rejmanová, J. Strohalm, B. Obereigner and Ulbrich, K, Polymers containing enzymatically degradable bonds. 4. Preliminary experiments in vivo, Makromol. Chem., 182, 2941-2949 (1981).
98. J. Kopeček, N. L. Krinick, B. Říhová and K. Ulbrich, Targetabtle N-(2-hydroxypropyl)methacrylamide copolymer chlorin e6 conjugates, Proceedings. SPIE,. 1203, 144-152 (1990).
99. J. Kopeček, P. Rejmanová and V. Chytrý, Polymers containing enzymatically degradable bonds. 1. Chymotrypsin catalyzed hydrolysis of p-nitroanilides of phenylalanine and tyrosine attached to side-chains of copolymers of N-(2-hydroxypropyl)methacrylamide, Makromol. Chem., 182, 799-809 (1981).
100. J. Kopeček, K. Ulbrich, E. I. Zacharieva, M. P. Georgieva and S. Kabaivanov, Polymers with anticancer activity and methods of their preparation, (PV 5354-81), CZ 223 417, Czechoslovakia (1986).
101. M. Kovář, J. Strohalm, T. Etrych, K. Ulbrich and B. Říhová, Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: A novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect, Bioconjugate Chem., 13, 206-215 (2002).
102. F. Kratz, K. Abu Ajaj and A. Warnecke, Anticancer carrierlinked prodrugs in clinical trials, Expert Opin. Investig. Drugs, 16, 1037-1058 (2007).
103. F. Kratz, I. A. Muller, Ryppa and A. Warnecke, Prodrug strategies in anticancer chemotherapy, Chemmedchem, 3, 20-53 (2008).
104. H. R. Kricheldorf, Polypeptides and 100 years of chemistry of α-amino acid N-carboxyanhydrides, Angew. Chem. Int. Edit., 45, 5752-5784 (2006).
105. N. L. Krinick, B. Říhová, K. Ulbrich, J. D. Andrade and J. Kopecěk, Targetable photoactivatable drugs. 1. Synthesis of water-soluble galactosamine containing polymeric carriers of chlorin e6 and their photodynamic effect on PLC cells in vitro, Proccedings SPIE, Adv. Photochemotherapy, 997, 77-83 (1988).
106. N. L. Krinick, B. Říhová, K. Ulbrich, J. Strohalm and J. Kopeček, Targetable photoactive drugs. 2. Synthesis of N-(2-hydroxypropyl)methacrylamide copolymer-anti-Thy 1.2 antibody-chlorin e6conjugates and a preliminary study of their photodynamic effect on mouse splenocytes in vitro, Makromol. Chem., 191, 839-856 (1990).
107. N. L. Krinick, Y. Sun, D. Joyner, J. D. Spikes, R. C. Straight and J. Kopeček, A polymeric drug-delivery system for the simultaneous delivery of drugs activatable by enzymes and or light, J. Biomat. Sci. -Polym. E., 5, 303-324 (1994).
108. A. Laane, V. Chytrý, M. Haga, P. Sikk, A. Aaviksaar and J. Kopeček, Covalent attachment of chymotrypsin to poly[N-(2-hydroxypropyl)methacrylamide], Collect. Czech. Chem. Commun., 46, 1466-1473 (1981).
109. N. Lavignac, M. Lazenby, J. Franchini, P. Ferruti and R. Duncan, Synthesis and preliminary evaluation of poly(amidoamine)-melittin conjugates as endosomolytic polymers and/or potential anticancer therapeutics, Int. J. Pharm., 300, 102-112 (2005).
110. D. Le Garrec, M. Ranger and J. C. Leroux, Micelles in Anticancer Drug Delivery, American Journal of Drug Delivery, 2, 15-42 (2004).
111. Y. Levy, M. S. Hershfield, C. Fernandezmejia, S. H. Polmar, D. Scudiery, M. Berger and R. U. Sorensen, Adenosine-deaminase deficiencywith late onset of recurrent infections response to treatment with polyethylene-glycol modified adenosine-deaminase, J. Pediatr., 113, 312-317 (1988).
112. C. Li and S. Wallace, Polymer-drug conjugates: Recent development in clinical oncology, Adv. Drug Delivery Rev., 60, 886-898 (2008).
113. M. Ligeti, G. Mezo, K. Marko, E. Madarasz and F. Hudecz, Conjugation of a cyclic rgd derivative to branched chain polymeric polypeptide: Synthesis and biological study of AK-(cyclo[RGDfC])), J. Pept. Sci., 12, 178 (2006).
114. C. Lin, C. J. Blaauboer, M. M. Timoneda, M. C. Lok, M. van Steenbergen, W. E. Hennink, Z. Y. Zhong, J. Feijen and J. F. J. Engbersen, Bioreducible poly(amido amine)s with oligoamine side chains: Synthesis, characterization, and structural effects on gene delivery, J. Control. Release, 126, 166-174 (2008).
115. X. Lin, Q. Zhang, J. R. Rice, D. R. Stewart, D. P. Nowotnik and S. B .Howell, Improved targeting of platinum chemotherapeutics: the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models, Eur. J. Cancer, 40, 291-297 (2004).
116. B. R. Line, A. Mitra, A. Nan and H. Ghandehari, Targeting tumor angiogenesis: Comparison of peptide and polymer-peptide conjugates, J. Nucl. Med., 46, 1552-1560 (2005).
117. J. Liu, S. Ohta, A. Sonoda, M. Yamada, M. Yamamoto, N. Nitta, K. Murata and Y. Tabata, Preparation of PEG-conjugated fullerene containing Gd3+ ions for photodynamic therapy, J. Control. Release, 117, 104-110 (2007).
118. J. Y. Ljubimova, M. Fujita, N. M. Khazenzon, B. S. Lee, S. Wachsmann-Hogiu, D. L. Farkas, K. L. Black and E. Holler, Nanoconjugate based on polymalic acid for tumor targeting, Chem. -Biol. Interact., 171, 195-203 (2008).
119. J. B. Lloyd, R. Duncan and J. Kopeček, Synthetic polymers as targetable carriers for drugs, Pure Appl. Chem., 56, 1301-1304 (1984).
120. S. Loethen, J. M. Kim and D. H. Thompson, Biomedical applications of cyclodextrin based polyrotaxanes, Polym. Rev., 47, 383-418 (2007).
121. Z. R. Lu, S. Q. Gao, P. Kopečková and J. Kopeček, Modification of cyclosporin A and conjugation of its derivative to HPMA copolymers, Bioconjugate Chem., 12, 129-133 (2001).
122. Lu, Z. R., Kopečková, P. and Kopeček, J, Polymerizable Fab' antibody fragments for targeting of anticancer drugs, Nat. Biotechnol., 17, 1101-1104 (1999).
123. Z. R. Lu, J. G. Shiah, P. Kopečková and J. Kopeček, Preparation and biological evaluation of polymerizable antibody Fab' fragment targeted polymeric drug delivery system, J. Control. Release, 74, 263-268 (2001).
124. Z. R. Lu, J. G. Shiah, P. Kopečková and Kopeček, J, Polymerizable Fab' antibody fragment targeted photodynamic cancer therapy in nude mice, STP Pharma Sci., 13, 69-75 (2003).
125. H. Maeda, SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy, Adv. Drug Delivery Rev., 46, 169-185 (2001a).
126. H. Maeda, K. Greish and J. Fang, The EPR effect and polymeric drugs: A paradigm shift for cancer chemotherapy in the 21st century, in Advances in Polymer Science, Springer, Berlin/Heidelberg, 103-121 (2006).
127. H. Maeda, T. Konno, Neocarzinostatin: The Past, Present and Future of an Anticancer Drug, Eds., H. Maeda, K. Edo and N. Ishida, Springer, Berlin (1997).
128. H. Maeda, T. Sawa and T. Konno, Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS, J. Control. Release, 74, 47-61 (2001).
129. H. Maeda, L. W. Seymour and Y. Miyamoto, Conjugates of anticancer agents and polymers - advantages of macromolecular therapeutics in vivo, Bioconjugate Chem., 3, 351-362 (1992).
130. A. Mero, G. Pasut, L. D. Via, M. W. M. Fijten, U. S. Schubert, R. Hoogenboom and F. M. Veronese, Synthesis and characterization of poly(2-ethyl 2-oxazoline)-conjugates with proteins and drugs: Suitable alternatives to PEG-conjugates? J. Control. Release, 125, 87-95 (2008).
131. Z. Miklan, J. Remenyi, G. Schlosser, D. Andreu and F. Hudecz, Synthesis and in vitro antitumour activity of new antifolate drugpeptide conjugates, J. Pept. Sci., 12, 216 (2006).
132. A. Mitra, T. Coleman, M. Borgman, A. Nan, H. Ghandehari and B. R. Line, Polymeric conjugates of mono- and bi-cyclic αVβ3 binding peptides for tumor targeting, J. Control. Release, 114, 175-183 (2006).
133. A. Mitra, J. Mulholland, A. Nan, E. McNeill, H. Ghandehari and B. R. Line, Targeting tumor angiogenic vasculature using polymer-RGD conjugates, J. Control. Release, 102, 191-201 (2005).
134. A. Mitra, A. Nan, B. R. Line and H. Ghandehari, Nanocarriers for nuclear imaging and radiotherapy of cancer, Curr. Pharm. Design, 12, 4729-4749 (2006).
135. A. Mitra, A. Nan, J. C. Papadimitriou, H. Ghandehari and B. R. Line, Polymer-peptide conjugates for angiogenesis targeted tumor radiotherapy, Nucl. Med. Biol., 33, 43-52 (2006).
136. A.M. Mohs, X. H. Wang, K. C. Goodrich, Y. D. Zong, D. L. Parker and Z. R. Lu, PEG-g-poly(GdDTPA-co-L-cystine): A biodegradable macromolecular blood pool contrast agent for MR imaging, Bioconjugate Chem., 15, 1424-1430 (2004).
137. A. M. Mohs, Y. D. Zong, J. Y. Guo, D. L. Parker and Z. R. Lu, PEG-g-poly(GdDTPA-co-L-cystine): Effect of PEG chain length on in vivo contrast enhancement in MRI, Biomacromolecules, 6, 2305-2311 (2005).
138. C. Moon, Y.M. Kwon, W. K. Lee, Y. J. Park and V. C. Yang, In vitro assessment of a novel polyrotaxane-based drug delivery system integrated with a cell-penetrating peptide, J. Control. Release, 124, 43-50 (2007).
139. T. Mori, Cancer-specific ligands identified from screening of peptide-display libraries, Current Pharmaceutical Design, 10, 2335-2343 (2004).
140. T. Mrkvan, M. Šírová, T. Etrych, P. Chytil, J. Strohalm, D. Plocová, K. Ulbrich and B. Říhová, Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor immunity, J. Control. Release, 110, 119-129 (2005).
141. D. D. N'Da and E. W. Neuse, Polyamidoamines as drug carriers: Synthesis of polymers featuring extrachain-type primary amino groups as drug-anchoring sites, South Afr. J. Chem. -Suid-Afr. Tydskr. Chem., 59, 65-U12 (2006).
142. D. D. N'Da, E.W. Neuse and C. E. J. van Rensburg, Carrier-bound methotrexate. IV. Antiproliferative activity of polyaspartamide- MTX conjugates against leukemic lymphoblast cell lines, South Afr. J. Chem. -Suid-Afr. Tydskr. Chem., 59, 135-140 (2006).
143. T. Nakanishi, S. Fukushima, K. Okamoto, M. Suzuki, Y. Matsumura, M. Yokoyama, T. Okano, Y. Sakurai and K. Kataoka, Development of the polymer micelle carrier system for doxorubicin, J. Control. Release, 74, 295-302 (2001).
144. A. Nan, S. L. Croft, V. Yardley and H. Ghandehari, Targetable water-soluble polymer-drug conjugates for the treatment of visceral leishmaniasis, J. Control. Release, 94, 115-127 (2004).
145. E. W. Neuse and G. Caldwell, cis-Diaminedichloroplatinum(II) complexes reversibly linked into the main chain of water-soluble polyamides, Journal of Inorganic and Organometallic Polymers, 7, 163-181 (1997).
146. E.W.M. Ng, D. T. Shima, P. Calias, E. T. Cunningham, D. R. Guyer and A. P. Adamis, Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease, Nat. Rev. Drug Discov., 5, 123-132 (2006).
147. M. Nichifor and G. Mocanu, Polysaccharide-drug conjugates as controlled drug delivery systems, in Polysaccharides for Drug Delivery and Pharmaceutical Applications, Eds., R. H. Marchessault, F. Ravenelle and X. X. Zhu, OxfordUniversity Press, Oxford, 289-303 (2006).
148. N. Nishiyama, A. Nori, A. Malugin, Y. Kasuya, P. Kopečková and J. Kopeček, Free and N-(2-hydroxypropyl)methacrylamide copolymer-bound geldanamycin derivative induce different stress responses in A2780 human ovarian carcinoma cells, Cancer Res., 63, 7876-7882 (2003).
149. Y. Noguchi, J. Wu, R. Duncan, J. Strohalm, K. Ulbrich, T. Akaike and H. Maeda, Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues, Jpn. J. Cancer Res., 89, 307-314 (1998).
150. A. Nori, K. D. Jensen, M. Tijerina, P. Kopečková and J. Kopeček, Subcellular trafficking of HPMA copolymer-Tat conjugates in human ovarian carcinoma cells, J. Control. Release, 91, 53-59 (2003).
151. A. Nori, K. D. Jensen, M. Tijerina, P. Kopečková and J. Kopeček, Tat-conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells, Bioconjugate Chem., 14, 44-50 (2003).
152. A. Nori and J. Kopeček, Intracellular targeting of polymer-bound drugs for cancer chemotherapy, Adv. Drug Delivery Rev., 57, 609-636 (2005).
153. K. B. O'Hare, R. Duncan, J. Strohalm, K. Ulbrich and P. Kopečková, Polymeric drug-carriers containing doxorubicin and melanocyte-stimulating hormone: in vitro and in vivo evaluation against murine melanoma, J. Drug Targeting, 1, 217-229 (1993).
154. Y. Ohya, K. Hirai and T. Ouchi, Synthesis and cytotoxic activity of doxorubicin bound to poly(α-malic acid) via ester or amide bonds, Makromol. Chem., 193, 1881-1887 (1992).
155. T. Ooya and N. Yui, Synthesis and characterization of biodegradable polyrotaxane as a novel supramolecular-structured drug carrier, J. Biomat. Sci. -Polym. E., 8, 437-455 (1997).
156. T. Ooya and N. Yui, Polyrotaxanes: Synthesis, structure, and potential in drug delivery, Crit. Rev. Ther. Drug Carr. Syst., 16, 289-330 (1999).
157. D. Oupický, K. Ulbrich and B. Říhová, Conjugates of semitelechelic poly[N-(2-hydroxypropyl)methacrylamide] with enzymes for protein delivery, J. Bioact. Compat. Polym., 14, 213-231 (1999).
158. J. H. Park, S. Lee, J. H. Kim, K. Park, K. Kim and I. C. Kwon, Polymeric nanomedicine for cancer therapy, Prog. Polym. Sci., 33, 113-137 (2008).
159. G. Pasut, F. Canal, L. D. Via, S. Arpicco, F. A. Veronese and O. Schiavon, Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid, J. Control. Release, 127, 239-248 (2008).
160. G. Pasut, S. Scaramuzza, O. Schiavon, R. Mendichi and F. M Veronese, PEG-epirubicin conjugates with high drug loading, J. Bioactive Compat. Polym., 20, 213-230 (2005).
161. G. Pasut, M. Sergi and F.M. Veronese, Anti-cancer PEG-enzymes: 30 years old, but still a current approach, Adv. Drug Delivery Rev., 60, 69-78 (2008).
162. G. Pasut and F. M. Veronese, Polymer-drug conjugation, recent achievements and general strategies, Prog. Polym. Sci., 32, 933-961 (2007).
163. G. Pasut and F. Veronese, PEGylation of Proteins as Tailored Chemistry for Optimized Bioconjugates, in Advances in Polymer Science: Polymer Therapeutics I, Eds., R. Satchi-Fainaro and R. Duncan, Springer-Verlag, Berlin/Heidelberg, 95-134 (2006).
164. M. Pechar, A. Braunová and K. Ulbrich, Poly(ethylene glycol)- based polymer carrier of doxorubicin degradable by both enzymatic and chemical hydrolysis, Collect. Czech. Chem. Commun., 70, 327-338 (2005).
165. M. Pechar, K. Ulbrich, M. Jelínková and B. Říhová, Enzymatically degradable PEG multiblock copolymers with hydrazoneattached doxorubicin in cancer therapy, J. Control. Release, 72, 253-254 (2001).
166. M. Pechar, K. Ulbrich, V. Šubr, L.W. Seymour and E. H. Schacht, Poly(ethylene glycol) multiblock copolymer as a carrier of anticancer drug doxorubicin, Bioconjugate Chem., 11, 131-139 (2000).
167. A. Pendri, C. D. Conover and R. B. Greenwald, Antitumor activity of paclitaxel-2'-glycinate conjugated to poly(ethylene glycol): A water-soluble prodrug, Anti-Cancer Drug Design, 13, 387-395 (1998).
168. P. J. Pockros, R. Carithers, P. Desmond, D. Dhumeaux, M.W. Fried, P. Marcellin, M. L. Shiffman, G. Minuk, K. R. Reddy, R. W. Reindollar, A. Lin and M. J. Brunda, Efficacy and safety of two-dose regimens of peginterferon α-2a compared with interferon α-2a in chronic hepatitis C: A multicenter, randomized controlled trial, Am. J. Gastroenterol., 99, 1298-1305 (2004).
169. R. Pola, M. Pechar, K. Ulbrich and A. Fabra, Polymer-doxorubicin conjugate with a synthetic peptide ligand targeted on prostate tumor, J. Bioact. Compat. Polym., 22, 602-620 (2007).
170. P. Poučková, M. Zadinová, D. Hloušková, J. Strohalm, D. Plocová, M. Špunda, T. Olejár, M. Zitko, J. Matoušek, K. Ulbrich and J. Souček, Polymer-conjugated bovine pancreatic and seminal ribonucleases inhibit growth of human tumors in nude mice, J. Control. Release, 95, 83-92 (2004).
171. M. Przybylski, D. S. Zaharko, M. A. Chirigos, R. H. Adamson, R. M. Schultz and H. Ringsdorf, Divemamethotrexate - immune-adjuvant role of polymeric carriers linked to anti-tumor agents, Cancer Treatment Rep., 62, 1837-1843 (1978).
172. D. Putnam and J. Kopeček, Enantioselective release of 5-fluorouracil from N-(2-hydroxypropyl)methacrylamide-based copolymers via lysosomal-enzymes, Bioconjugate Chem., 6, 483-492 (1995).
173. D. Putnam and J. Kopeček, Polymer conjugates with anticancer activity, Adv. Polym. Sci., 122, 55-123 (1995).
174. D. A. Putnam, J. G. Shiah and J. Kopeček, Intracellularly biorecognizable derivatives of 5-fluorouracil - implications for sitespecific delivery in the human condition, Biochem. Pharmacol., 52, 957-962 (1996).
175. J. Pytela, J. Jakeš and F. Rypáček, A study of enzymatic degradation of a macromolecular substrate, poly[N5-(2-hydroxyethyl)-Lglutamine], by gel-permeation chromatography and kineticmodeling, Int. J. Biol.Macromol., 16, 15-20 (1994).
176. J. M. Rademaker-Lakhai, C. Terret, S. B. Howell, C. M. Baud, R. F. de Boer, D. Pluim, J. H. Beijnen, J. H. M. Schellens and J. P. Droz, A phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors, Clin. Cancer Res., 10, 3386-3395 (2004).
177. P. Rejmanová, J. Kopeček, J. Pohl, M. Baudyš and V. Kostka, Polymers containing enzymatically degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)-methacrylamide copolymers by bovine spleen cathepsin B, Makromol. Chem., 184, 2009-2020 (1983).
178. P. Rejmanová, B. Obereigner and J. Kopeček, Polymers containing enzymatically degradable bonds. 2. Poly[N-(2- hydroxypropyl)methacrylamide] chains connected by oligopeptide sequences cleavable with chymotrypsin, Makromol. Chem., 182, 1899-1915 (1981).
179. J. R. Rice and S. B. Howell, AP-5346. Polymer-delivered platinum complex, Drugs of the Future, 29, 561-565 (2004).
180. B. Říhová, Immunomodulating activities of soluble synthetic polymer-bound drugs, Adv. Drug Delivery Rev., 54, 653-674 (2002).
181. B. Říhová, Anti body-targeted HPMA copolymer-bound anthracycline antibiotics, Drug Future, 28, 1189-1210 (2003).
182. B. Říhová, Biocompatibility and immunocompatibility of watersoluble polymers based on HPMA, Compos. Part B-Eng., 38, 386-397 (2007).
183. B. Říhová, T. Etrych, M. Pechar, M. Jelínková, M. Št'astný, O. Hovorka, M. Kovář and K. Ulbrich, Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes, J. Control. Release, 74, 225-232 (2001).
184. B. Říhová, A. Jegorov, J. Strohalm, V. Mt'aha, P. Rossmann, L. Fornuůsek and K. Ulbrich, Antibody-targeted cyclosporin A, J. Control. Release, 19, 25-39 (1992).
185. B. Říhová, M. Jelínková, J. Strohalm, M. Šastný, O. Hovorka, D. Plocová, M. Kovář, L. Dráberová and K. Ulbrich, Antiproliferative effect of a lectin- and anti-Thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary andmetastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse Thy-1.2 gene, Bioconjugate Chem., 11, 664-673 (2000).
186. B. Říhová and J. Kopeček, Biological properties of targetable poly- [N-(2-hydroxypropyl)methacrylamide]-antibody conjugates, J. Control. Release, 2, 289-310 (1985).
187. B. Říhová, J. Kopeček, P. Kopečková-Rejmanová, J. Strohalm, D. Plocová andD. Semorádová, Bioaffinity therapy with antibodies and drugs bound to soluble synthetic polymers, J. Chromatogr. B, 376, 221-233 (1986).
188. B. Říhová, N. L. Krinick and J. Kopecěk, Targetable photoactivatable drugs. 3. In vitro efficacy of polymer-bound chlorin-e6 toward human hepatocarcinoma cell-line (Plc/Prf/5) targeted with galactosamine and to mouse splenocytes targeted with anti-Thy 1.2 antibodies, J. Control. Release, 25, 71-87 (1993).
189. B. Říhová, J. Strohalm, O. Hovorka, O. Šubr, T. Etrych, P. Chytil, R. Pola, D. Plocová, J. Bouček and K. Ulbrich, Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences, J. Control. Release, 127, 110-120 (2008).
190. B. Říhová, J. Strohalm, M. Kovář, T. Mrkvan, V. Šubr, O. Hovorka, M. Šírová, L. Rozprimová, K. Kubáčková and K. Ulbrich, Induction of systemic antitumour resistance with targeted polymers, Scand. J. Immunol., 62, 100-105 (2005).
191. B. Říhová, J. Strohalm, K. Kubáčková, M. Jelínková, L. Rozprimová, M. Šírová, D. Plocová, T. Mrkvan, M. Kovář, J. Pokorná, T. Etrych and K. Ulbrich, Drug-HPMA-HuIg conjugates effective against human solid cancer, in Polymer Drugs in the Clinical Stage: Advantages and Prospects, Eds. H. Maeda, A. Kabanov, K. Kataoka and T. Okano, Kluwer Academic/Plenum Publishers, New York, 125-143 (2003).
192. B. Řihová, J. Strohalm, D. Plocová and K. Ulbrich, Selectivity of antibody-targeted anthracycline antibiotics on T-lymphocytes, J. Bioactive Compat. Polym., 5, 249-266 (1990).
193. B. Říhová, J. Strohalm, J. Prausová, K. Kubáčková, M. Jelínková, L. Rozprimová, M. Šírová, D. Plocová, T. Etrych, V. Šubr, T. Mrkvan, M. Kovář and K. Ulbrich, Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data, J. Control. Release, 91, 1-16 (2003).
194. H. Ringsdorf, Structure and properties of pharmacologically active polymers, J. Polym. Sci., Polym. Symp., 135-153 (1975).
195. H. Ringsdorf, B. Schmidt and K. Ulbrich, Bis(2-chloroethyl)amine bound to copolymers of N-(2-hydroxypropyl)methacrylamide and methacryloylated oligopeptides via biodegradable bonds, Makromol. Chem., 188, 257-264 (1987).
196. P. C. A. Rodrigues, U. Beyer, P. Schumacher, T. Roth, H. H. Fiebig, C. Unger, L. Messori, P. Orioli, D. H. Paper, R. Mulhaupt and F. Kratz, Acid-sensitive polyethylene glycol conjugates of doxorubicin: Preparation, in vitro efficacy and intracellular distribution, Bioorg. Med. Chem., 7, 2517-2524 (1999).
197. F. Rypáček, W. R. Banks, D. Nosková and G. A. Digenis, Synthetic macromolecular inhibitors of human-leukocyte elastase. 1. Synthesis of peptidyl carbamates bound to water-soluble polymers - poly-α,β-[N-(2-hydroxyethyl)-D,L-aspartamide] and poly-α-[N5-(2-hydroxyethyl)-L-glutamine], J. Med. Chem., 37, 1850-1856 (1994).
198. F. Rypáček, J. Pytela, R. Kotva, V. Škarda and I. Cífková, Biodegradation of poly(amino acid)s: Evaluation methods and structureto-function relationships, Macromol. Symp., 123, 9-24 (1997).
199. S. Sakuma, Z. R. Lu, P. Kopečková and J. Kopeček, Biorecognizable HPMA copolymer-drug conjugates for colon-specific delivery of 9-aminocamptothecin, J. Control. Release, 75, 365-379 (2001).
200. S. Sakuma, Z. R. Lu, B. Pecharová, P. Kopečková and J. Kopeček, N-(2-hydroxypropyl)methacrylamide copolymer-9- aminocamptothecin conjugate: Colon-specific drug delivery in rats, J. Bioact. Compat. Polym., 17, 305-319 (2002).
201. L. Santucci, A. Mencarelli, B. Renga, G. Pasut, F. Veronese, A. Zacheo, A. Germani and S. Fiorucci, Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin, FASEB J., 20, 765-767 (2006).
202. N. Sarapa, M. R. Britto, W. Speed, M. Jannuzzo, M. Breda, C. A. James, M. Porro, M. Rocchetti, A. Wanders, H. Mahteme and P. Nygren, Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma, Cancer Chemother. Pharmacol., 52, 424-430 (2003).
203. R. Satchi, T.A. Connors and R. Duncan, PDEPT: polymer-directed enzyme prodrug therapy I. HPMA copolymer-cathepsin B and PK1 as a model combination, Br. J. Cancer, 85, 1070-1076 (2001).
204. R. Satchi-Fainaro, A. E. Birsner, C. Butterfield, L. Akslen, S. M. Short and J. Folkman, HPMA copolymer-TNP-470 (caplostatin) and Avastin show synergistic inhibition of human tumor growth in mice, EJC Supplements, 3, 15 (2005).
205. R. Satchi-Fainaro, R. Duncan and C. Barnes, Polymer therapeutics for cancer: Current status and future challenges, in Advances in Polymer Science: Polymer Therapeutics II, Eds. R. Satchi-Fainaro and R. Duncan, Springer-Verlag, Berlin/Heidelberg, 1-65 (2006).
206. R. Satchi-Fainaro, H. Hailu, J. W. Davies, C. Summerford and R Duncan, PDEPT: Polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-β-lactamase and HPMA copolymer-C-Dox as a model combination, Bioconjugate Chem., 14, 797-804 (2003).
207. R. Satchi-Fainaro, R. Mamluk, L. Wang, S. M. Short, J. A. Nagy, D. Feng, A. M. Dvorak, H. F. Dvorak, M. Puder, D. Mukhopadhyay and J. Folkman, Inhibition of vessel permeability by TNP- 470 and its polymer conjugate, caplostatin, Cancer Cell, 7, 251-261 (2005).
208. R. Satchi-Fainaro, M. Puder, J. W. Davies, H. T. Tran, D. A. Sampson, A. K. Greene, G. Corfas and J. Folkman, Targeting angiogenesiswith a conjugate of HPMA copolymer and TNP-470, Nat. Med., 10, 255-261 (2004).
209. C. W. Scales, Y. A. Vasilieva, A. J. Convertine, A. B. Lowe and C. L. McCormick, Direct, controlled synthesis of the nonimmunogenic, hydrophilic polymer, poly(N-(2-hydroxypropyl)methacrylamide) via RAFT in aqueous media, Biomacromolecules, 6, 1846-1850 (2005).
210. O. Schiavon, G. Pasut, S. Moro, P. Orsolini, A. Guiotto and F. M. Veronese, PEG-Ara-C conjugates for controlled release, Eur. J. Med. Chem., 39, 123-133 (2004).
211. T. Schluep, J. J. Cheng, K. T. Khin and M. E. Davis, Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice, Cancer Chemother. Pharmacol., 57, 654-662 (2006).
212. T. Schluep, J. Hwang, J. J. Cheng, J. D. Heidel, D. W. Bartlett, B. Hollister and M. E. Davis, Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models, Clin. Cancer Res., 12, 1606-1614 (2006).
213. N. E. Schoemaker, C. van Kesteren, H. Rosing, S. Jansen, M. Swart, J. Lieverst, D. Fraier, M. Breda, C. Pellizzoni, R. Spinelli, M. G. Porro, J. H. Beijnen, J. H.M. Schellens andW.W. T. Huinink, A phase I and pharmacokinetic study of MAG-CPT, a watersoluble polymer conjugate of camptothecin, Br. J. Cancer, 87, 608-614 (2002).
214. F. Searle, S. Gac-Breton, R. Keane, S. Dimitrijevic, S. Brocchini, E. A. Sausville and R. Duncan, N-(2-hydroxypropyl)methacrylamide copolymer-6-(3-aminopropyl)-ellipticine conjugates. Synthesis, in vitro, and preliminary in vivo evaluation, Bioconjugate Chem., 12, 711-718 (2001).
215. Sedlák, M., Drabina, P., Bílková, E., Šimnek, P. and Buchta, V, New targeting system for antimycotic drugs: β-Glucosidase sensitive Amphotericin B-star poly(ethylene glycol) conjugate, Bioorg. Med. Chem. Lett., 18, 2952-2956 (2008).
216. M. Sedlák, M. Pravda, L. Kubicová, P. Mikulčíková and K. Ventura, Synthesis and characterisation of a new pH-sensitive amphotericin B - poly(ethylenglycol)-b-poly(L-lysine) conjugate, Bioorg. Med. Chem. Lett., 17, 2554-2557 (2007).
217. M. Sedlák, M. Pravda, F. Staud, L. Kubicová, K. Týčová and K. Ventura, Synthesis of pH-sensitive amphotericin B-poly(ethylene glycol) conjugates and study of their controlled release in vitro, Bioorg. Med. Chem., 15, 4069-4076 (2007).
218. L. W. Seymour, R. Duncan, P. Kopečková-Rejmanová and J. Kopeček, Potential of sugar residues attached to N-(2- hydroxypropyl)methacrylamide copolymers as targeting groups for the selective delivery of drugs, J. Bioact. Compat. Polym., 2, 97-119 (1987).
219. L. W. Seymour, D. R. Ferry, D. Anderson, S. Hesslewood, P. J. Julyan, R. Poyner, J. Doran, A. M. Young, S. Burtles and D. J. Kerr, Hepatic drug targeting: Phase I evaluation of polymerbound doxorubicin, J. Clin. Oncol., 20, 1668-1676 (2002).
220. L. W. Seymour, P. A. Flanagan, A. Alshamkhani, V. Šubr, K. Ulbrich, J. Cassidy and R. Duncan, Synthetic-polymers conjugated to monoclonal-antibodies - vehicles for tumor-targeted drug delivery, Select. Cancer Ther., 7, 59-73 (1991).
221. L.W. Seymour, Y. Miyamoto, H. Maeda, M. Brereton, J. Strohalm, K. Ulbrich and R. Duncan, Influence of molecular-weight on passive tumor accumulation of a soluble macromolecular drug carrier, Eur. J. Cancer, 31A, 766-770 (1995).
222. L. W. Seymour, K. Ulbrich, S. R. Wedge, I. C. Hume, J. Strohalm and R. Duncan, N-(2-Hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor - pharmacokinetics in Dba2 mice, Br. J. Cancer, 63, 859-866 (1991).
223. S. A. Shaffer, C. Baker-Lee, J. Kennedy, M. S. Lai, P. De Vries, K. Buhler and J. W Singer, In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases, Cancer Chemother. Pharmacol., 59, 537-548 (2007).
224. J. G. Shiah, M. Dvořák, P. Kopečková, Y. Sun, C. M. Peterson and J. Kopeček, Biodistribution and antitumour efficacy of long-circulating N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in nude mice, Eur. J. Cancer, 37, 131-139 (2001).
225. M. Šírová, J. Strohalm, V. Šubr, D. Plocová, P. Rossmann, T. Mrkvan, K. Ulbrich and B. Říhová, Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice, Cancer Immunol. Immunother., 56, 35-47 (2007).
226. S. Sofou, Radionuclide carriers for targeting of cancer, Int. J. Nanomedicine, 1-19 (2008).
227. M. V. Solovskij, K. Ulbrich and J. Kopeček, Synthesis of N-(2-hydroxypropyl)methacrylamide copolymers with antimicrobial activity, Biomaterials, 4, 44-48 (1983).
228. M. V. Solovskij, K. Ulbrich, J. Kopeček, E. F. Panarin, G. E. Afinogenov and A. A. Domorad, Synthesis and study of polymeric derivatives of Gramicidin-S antibiotic, Russ. J. Appl. Chem., 67, 756-761 (1994).
229. J. Souček, P. Poučková, J. Strohalm, D. Plocová, D. Hloušková, M. Zadinová and K. Ulbrich, Poly[N-(2-hydroxypropyl)methacrylamide] conjugates of bovine pancreatic ribonuclease (RNase A) inhibit growth of human melanoma in nude mice, J. Drug Target., 10, 175-183 (2002).
230. J. Souček, P. Poučková, M. Zadinová, D. Hloušková, D. Plocová, J. Strohalm, Z. Hrkal, T. Olejár and K. Ulbrich, Polymer conjugated bovine seminal ribonuclease inhibits growth of solid tumors and development of metastases in mice, Neoplasma, 48, 127-132 (2001).
231. H. Soyez, E. Schacht, A. DeMarre and L. W. Seymour, Polymeric prodrugs of mitomycin C, Macromol. Symp., 103, 163-176 (1996a).
232. H. Soyez, E. Schacht and S. Vanderkerken, The crucial role of spacer groups in macromolecular prodrug design, Adv. Drug Delivery Rev., 21, 81-106 (1996b).
233. H. Soyez, L.W. Seymour and E. Schacht, Macromolecular derivatives of N,N-di-(2-chloroethyl)-4-phenylene diamine mustard. 2. In vitro cytotoxicity and in vivo anticancer efficacy, J. Control. Release, 57, 187-196 (1999).
234. M. Štastný, K. Ulbrich, J. Strohalm, P. Rossmann and B. Říhová, Abnormal differentiation of thymocytes induced by free cyclosporine is avoided when cyclosporine bound to N-(2-hydroxypropyl)methacrylamide copolymer carrier is used, Transplantation, 63, 1818-1827 (1997).
235. O. Štěrba, E. Paluska, O. Jozová, J. Spunda, J. Nezvalová, L. Šprincl, J. Kopeček and J. Činátl, New types of synthetic infusion solutions. Basic biological properties of poly-N-(2-hydroxypropyl)methacrylamide (in Czech), Čas. Lék. Česk., 114, 1268-1270 (1975).
236. V. Šubr, T. Etrych, K. Ulbrich, T. Hirano, T. Kondo, T. Todoroki, M. Jelínková and B. Říhová, Synthesis and properties of poly[N-(2-hydroxypropyl)methacrylamide] conjugates of superoxide dismutase, J. Bioact. Compat. Polym., 17, 105-122 (2002).
237. V. Šubr, J. Kopeček, J. Pohl, M. Baudyš and V. Kostka, Cleavage of oligopeptide side-chains in N-(2-hydroxypropyl)methacrylamide copolymers by mixtures of lysosomal enzymes, J. Control. Release, 8, 133-140 (1988).
238. V. Šubr, J. Strohalm, T. Hirano, Y. Ito and K. Ulbrich, Poly[N-(2- hydroxypropyl)methacrylamide] conjugates of methotrexate -Synthesis and in vitro drug release, J. Control. Release, 49, 123-132 (1997).
239. V. Šubr, J. Strohalm, K. Ulbrich, R. Duncan and I. C. Hume, Polymers containing enzymatically degradable bonds. 12. Effect of spacer structure on the rate of release of daunomycin and adriamycin from poly[N-(2-hydroxypropyl)methacrylamide] copolymer drug carriers in vitro and antitumor-activity measured in vivo, J. Control. Release, 18, 123-132 (1992).
240. V. Šubr and K. Ulbrich, Synthesis and properties of new N-(2-hydroxypropyl)methacrylamide copolymers containing thiazolidine-2-thione reactive groups, React. Funct. Polym., 66, 1525-1538 (2006).
241. P. J. Swart, T. Hirano, M. E. Kuipers, Y. Ito, C. Smit, M. Hashida, M. Nishikawa, L. Beljaars, D. K. F. Meijer and K. Poelstra, Targeting of superoxide dismutase to the liver results in antiinflammatory effects in rats with fibrotic livers, J. Hepatol., 31, 1034-1043 (1999).
242. J. M. M. Terwogt, W. W. T. Huinink, J. H. M. Schellens, M. Schot, I. A. M. Mandjes, M. G. Zurlo, M. Rocchetti, H. Rosing, F. J. Koopman and J. H. Beijnen, Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymerconjugated prodrug of paclitaxel, Anti-Cancer Drugs, 12, 315-323 (2001).
243. A. H. Thomson, P. A. Vasey, L. S. Murray, J. Cassidy, D. Fraier, E. Frigerio and C. Twelves, Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours, Br. J. Cancer, 81, 99-107 (1999).
244. K. B. Thurmond, J. McEwan, D. G. Moro, J. R. Rice, G. Russell-Jones, J. V. St John, P. Sood, D. R. Stewart and D. P. Nowotnik, Targeted and non-targeted polymer drug delivery systems, in ACS Symposium Series No. 923: Polymeric Drug De livery I: Particulate Drug Carriers, Eds. S. Svenson, An American Chemical Society Publication, Oxford, 137-154 (2006).
245. R. Tomlinson, J. Heller, S. Brocchini and R. Duncan, Polyacetaldoxorubicin conjugates designed for pH-dependent degradation, Bioconjugate Chem., 14, 1096-1106 (2003).
246. R. Tomlinson, M. Klee, S. Garrett, J. Heller, R. Duncan and S. Brocchini, Pendent chain functionalized polyacetals that display pH-dependent degradation: A platform for the development of novel polymer therapeutics, Macromolecules, 35, 473-480 (2002).
247. V. P. Torchilin, Targeted pharmaceutical nanocarriers for cancer therapy and Imaging, AAPS Journal, 9, E128-E147 (2007).
248. K. Ulbrich, T. Etrych, P. Chytil, M. Jelínková and B. Říhová, HPMA copolymers with pH-controlled release of doxorubicin - In vitro cytotoxicity and in vivo antitumor activity, J. Control. Release, 87, 33-47 (2003).
249. K. Ulbrich, T. Etrych, P. Chytil, M. Jelínková and B. Říhová, Antibody-targeted polymer-doxorubicin conjugates with pHcontrolled activation, J. Drug Target., 12, 477-489 (2004).
250. K. Ulbrich, T. Etrych, P. Chytil, M. Pechar, M. Jelínková and B. Říhová, Polymeric anticancer drugs with pH-controlled activation, Int. J. Pharm., 277, 63-72 (2004).
251. K. Ulbrich, O. Nazarova, E. Panarin, M. Baudyš and M. V. Solovskij, In vitro release of chloramphenicol from poly[N-(2-hydroxypropyl)methacrylamide] carriers by cathepsin-B, Collect. Czech. Chem. Commun., 53, 1078-1085 (1988).
252. K. Ulbrich, J. Strohalm, D. Plocová, D. Oupický, V. Šubr, J. Souček, P. Poučková and J. Matoušek, Poly[N-(2-hydroxypropyl)- methacrylamide] conjugates of bovine seminal ribonuclease. Synthesis, physicochemical, and preliminary biological evaluation, J. Bioact. Compat. Polym., 15, 4-26 (2000).
253. K. Ulbrich, J. Strohalm, V. Šubr, D. Plocová, R. Duncan and B. Říhová, Polymeric conjugates of drugs and antibodies for sitespecific drug delivery, Macromol. Symp., 103, 177-192 (1996).
254. K. Ulbrich, V. Šubr, J. Strohalm, D. Plocová, M. Jelínková and B. Říhová, Polymeric drugs based on conjugates of synthetic and natural macromolecules I. Synthesis and physico-chemical characterisation, J. Control. Release, 64, 63-79 (2000).
255. K. Ulbrich, E. I. Zacharieva, J. Kopeček, I. C. Hume and R. Duncan, Polymer-bound derivatives of sarcolysin and their antitumor activity against mouse and human leuaemia in vitro, Makromol. Chem., 188, 2497-2509 (1987).
256. K. Ulbrich, E. I. Zacharieva, B. Obereigner and J. Kopeček, Polymers containing enzymatically degradable bonds. 5. Hydrophilic polymers degradable by papain, Biomaterials, 1, 199-204 (1980).
257. P. A. Vasey, R. Duncan, S. B. Kaye and J. Cassidy, Clinical phase I trial of PK1 (HPMA co-polymer doxorubicin), Eur. J. Cancer, 31A, 929 (1995).
258. P. A. Vasey, S. B. Kaye, R. Morrison, C. Twelves, P. Wilson, R. Duncan, A. H. Thomson, L. S. Murray, T. E. Hilditch, T. Murray, S. Burtles, D. Fraier, E. Frigerio and J. Cassidy, Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents - drugpolymer conjugates, Clin. Cancer Res., 5, 83-94 (1999).
259. F. M. Veronese and G. Pasut, Drug-polymers conjugates, in ComprehensiveMedicinal Chemistry II, Eds. D. J. Triggle and J. B. Taylor, Elsevier, Oxford, 1043-1068 (2007).
260. F. M. Veronese, O. Schiavon, G. Pasut, R. Mendichi, L. A. Andersson, Tsirk, J. Ford, G. F. Wu, S. Kneller, J. Davies and R. Duncan, PEG-doxorubicin conjugates: Influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity, Bioconjugate Chem., 16, 775-784 (2005).
261. D. Wang, P. Kopečková, T. Minko, V. Nanayakkara and J. Kopeček, Synthesis of star-like poly- [N-(2-hydroxypropyl)- methacrylamide] using PAMAM dendrimer as the core, ACS Polym. Preprints, Div. Polym. Chem., 41, 994-995 (2000).
262. D. Wang, P. Kopečková, T. Minko, V. Nanayakkara and J. Kopeček, Synthesis of starlike N-(2-hydroxypropyl)methacrylamide copolymers: Potential drug carriers, Biomacromolecules, 1, 313-319 (2000).
263. D. Wang, S. Miller, M. Sima, P. Kopečková and J. Kopeček, Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems, Bioconjugate Chem., 14, 853-859 (2003).
264. Y. S. Wang, S. Youngster, M. Grace, J. Bausch, R. Bordens and D. F. Wyss, Structural and biological characterization of pegylated recombinant interferon α-2b and its therapeutic implications, Adv. Drug Delivery Rev., 54, 547-570 (2002).
265. P. Wipf and W. Li, Prodrugs of ara-C, Drug Future, 19, 49-54 (1994).
266. S. Wroblewski, M. Berenson, P. Kopečková and J. Kopeček, Potential of lectin-N-(2-hydroxypropyl)methacrylamide copolymerdrug conjugates for the treatment of pre-cancerous conditions, J. Control. Release, 74, 283-293 (2001).
267. S. Wroblewski, B. Říhová, P. Rossmann, T. Hudcovicz, Z. Rehakova, P. Kopečková and J. Kopeček, The influence of a colonic microbiota on HPMA copolymer lectin conjugates binding in rodent intestine, J. Drug Target, 9, 85-94 (2001).
268. S. Zalipsky, C. Gilon and A. Zilkha, Attachment of drugs to polyethylene glycols, Eur. Polym. J., 19, 1177-1183 (1983).
269. W. C. Zamboni, Concept and clinical evaluation of carriermediated anticancer agents, Oncologist, 13, 248-260 (2008).
270. H. Zhao, R. B. Greenwald, P. Reddy, J. Xia and P. Peng, A new platform for oligonucleotide delivery utilizing the PEG prodrug approach, Bioconjugate Chem., 16, 758-766 (2005).
271. H. Zhao, C. Lee, P. K. Sai, Y. H. Choe, M. Boro, A. Pendri, S. Y. Guan and R. B. Greenwald, 20-O-acylcamptothecin derivatives: Evidence for lactone stabilization, J. Org. Chem., 65, 4601-4606 (2000).
272. H. Zhao, B. Rubio, P. Sapra, D. C. Wu, P. Reddy, P. Sai, A. Martinez, Y. Gao, Y. Lozanguiez, C. Longley, L. M. Greenberger and I. D Horak, Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers, Bioconjugate Chem., 19, 849-859 (2008).
273. M. Zovko, B. Zorc, P. Novak, P. Tepes, B. Cetina-Cizmek and M. Horvat, Macromolecular prodrugs XI. Synthesis and characterization of polymer-estradiol conjugate, Int. J. Pharm., 285, 35-41 (2004).